Enabling a future where cancer is routinely detected early
Mi2 Holdings was founded to fundamentally change the imaging and treatment of cancer.
Mi2 Holdings was founded to fundamentally change the imaging and treatment of cancer.
A new generation of MR imaging agents that will revolutionize the detection of early-stage cancer and provide enhanced diagnostics for later stage cancer.
Delivering a new standard of image resolution by directly imaging only the cancer, NanoMark uses no radioactive sources or heavy metals and is compatible with existing MRI assets.
Created in collaboration with leading research US institutions the science is proven and patented.
Houston, TX